Financial Performance - The company's operating revenue for Q1 2024 was CNY 422,024,144.62, representing a year-on-year increase of 20.93%[5] - The net profit attributable to shareholders for the same period was CNY 56,048,131.61, with a growth of 2.03% compared to the previous year[5] - The basic earnings per share (EPS) was CNY 0.14, reflecting an increase of 7.69% year-on-year[5] - The net profit for Q1 2024 was ¥56,860,529.64, representing a 6.9% increase from ¥53,396,249.70 in Q1 2023[17] - In Q1 2024, the company reported a net profit of 56,860,529.64 RMB, an increase from 53,396,249.70 RMB in Q1 2023, representing a growth of approximately 4.3%[18] - The overall comprehensive income attributable to the parent company was 56,048,131.61 RMB in Q1 2024, up from 54,932,724.23 RMB in Q1 2023, reflecting a growth of approximately 2%[18] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 2,946,600,361.23, a slight increase of 0.90% from the end of the previous year[6] - The total assets of the company as of March 31, 2024, were ¥2,946,600,361.23, slightly up from ¥2,920,451,107.53 at the end of 2023[14] - The total liabilities decreased to ¥1,155,505,033.80 from ¥1,211,097,697.17 at the end of 2023, indicating a reduction in financial obligations[14] - The company's equity attributable to shareholders increased to ¥1,539,903,554.84 from ¥1,470,311,172.51 at the end of 2023, indicating growth in shareholder value[14] Cash Flow - The net cash flow from operating activities was CNY 6,107,280.58, showing improvement as the previous year's figure was negative[5][7] - Cash flow from operating activities generated a net cash inflow of 6,107,280.58 RMB in Q1 2024, a significant improvement from a net outflow of -1,351,706.77 RMB in Q1 2023[21] - The company received 462,161,879.85 RMB in cash from sales of goods and services in Q1 2024, compared to 330,487,785.44 RMB in Q1 2023, marking a growth of about 39.8%[21] - Cash outflows for operating activities totaled 458,773,664.15 RMB in Q1 2024, compared to 339,248,689.86 RMB in Q1 2023, indicating an increase of approximately 35.3%[21] - The company reported a net cash outflow from investing activities of -10,385,541.40 RMB in Q1 2024, an improvement from -112,077,228.06 RMB in Q1 2023[21] - Cash inflow from financing activities in Q1 2024 was 24,200,000.00 RMB, with a net cash inflow of 16,865,454.05 RMB after financing outflows, compared to a net outflow of -2,223,791.67 RMB in Q1 2023[22] Shareholder Information - The company had a total of 22,032 common shareholders at the end of the reporting period[9] - The largest shareholder, Zhang Hai, holds 46.03% of the shares, with 94,145,600 shares pledged[10] Costs and Expenses - The total operating costs for Q1 2024 were ¥354,161,051.46, up 22.4% from ¥289,432,187.31 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥8,891,832.83, an increase of 77.5% compared to ¥5,014,006.28 in Q1 2023[17] Inventory and Receivables - The company reported a significant increase in accounts receivable, totaling ¥551,144,801.91 as of March 31, 2024, compared to ¥546,266,433.92 at the end of 2023[12] - The inventory level rose to ¥231,895,435.21 as of March 31, 2024, compared to ¥175,724,948.92 at the end of 2023, reflecting increased stock levels[12] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]

Financial Performance - The audited net profit attributable to shareholders for 2023 is CNY 292,702,869.34, with the parent company's distributable profit at CNY 694,947,388.84[4] - In 2023, the company's operating revenue reached RMB 1.63 billion, a year-on-year increase of 36.10%[21] - The net profit attributable to shareholders was RMB 292.70 million, up 45.42% compared to the previous year[21] - The net profit after deducting non-recurring gains and losses was RMB 245.65 million, reflecting a 26.21% increase year-on-year[21] - Total assets increased by 60.76% year-on-year, reaching RMB 2.92 billion, primarily due to the mergers with Hanfang Pharmaceutical and Wudi Pharmaceutical[21] - The weighted average return on equity rose to 21.45%, an increase of 3.71 percentage points from the previous year[22] - The company achieved a net cash flow from operating activities of RMB 276.70 million, a decrease of 5.65% compared to the previous year[21] - The company’s equity attributable to shareholders increased by 18.66% year-on-year, amounting to RMB 1.47 billion[21] - The company reported a significant increase in manufacturing costs for the pharmaceutical sector, rising by 207.64% to CNY 51,076,010.22[71] - The company reported a total of 2,282 employees, with 1,316 in the parent company and 966 in major subsidiaries[157] Profit Distribution - The proposed profit distribution plan for 2023 is a cash dividend of CNY 2.00 per 10 shares (tax included), with no bonus shares or capital reserve conversion[4] - The total cash dividend amount, including the repurchase of shares, is RMB 111,645,063.20, accounting for 38.14% of the net profit attributable to ordinary shareholders in the consolidated financial statements[164] - The total cash dividend to be distributed is RMB 81,650,263.20, which represents a cash dividend ratio of 27.90% of the net profit attributable to ordinary shareholders in the consolidated financial statements[161] Compliance and Governance - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting potential risks[5] - The company confirms that there are no violations in decision-making procedures for external guarantees[7] - The board of directors and management guarantee the authenticity and completeness of the annual report, with no significant omissions[10] - The company operates under the regulatory guidance of the China Securities Regulatory Commission and the Shanghai Stock Exchange[13] - The company has held four shareholder meetings in 2023, ensuring compliance with legal and regulatory requirements[141] Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings, particularly in the OTC and traditional medicine sectors[13] - The company has diversified its product structure and expanded its marketing team to enhance OTC channel development[29] - The company expanded its sales channels, adding over 700 hospital channels and 600 small chain pharmacies, significantly boosting product sales stability[36] - The company is actively collaborating with hospitals and universities for clinical research, enhancing the evidence base for its core products and addressing the efficacy of traditional Chinese medicine[38] - The company is committed to exploring mergers and acquisitions in the health sector to drive significant growth and expand its pharmaceutical footprint[132] Research and Development - The company is committed to advancing digital production and research transformation to enhance its core competitiveness in the traditional Chinese medicine sector[39] - The company has established long-term strategic partnerships with multiple research institutions and universities to improve product quality and safety, focusing on new product development and existing product evaluations[55] - The company is conducting a multi-center clinical trial for its core product, the throat spray, expected to be completed within three years[96] - The company is developing several new traditional Chinese medicine products, including Xie Bai San and Qiang Huo Sheng Shi Tang, which are currently in the pharmaceutical research stage[100] - The company has ongoing research on the efficacy and safety of the "Qi Jiao Sheng Bai Capsule," which is aimed at treating symptoms related to blood deficiency, with plans for market launch after further studies[105] Environmental Responsibility - The company invested CNY 3.71 million in environmental protection during the reporting period[171] - The wastewater treatment facility has a capacity of 100 tons per day, achieving over 98% removal rates for COD and ammonia nitrogen[174] - The company has a dedicated hazardous waste storage facility, managed by specialized personnel, ensuring compliance with pollution control standards[176] - The company has established emergency response plans for environmental incidents, filed with local environmental protection agencies[178] - The company has a comprehensive environmental self-monitoring plan in place, ensuring regular assessments of emissions and wastewater quality[180] Human Resources and Management - The company has a structured management team with a mix of experienced professionals, ensuring continuity in leadership and strategic direction[143] - The total remuneration for the reporting period for directors and senior management amounted to 437.83 million yuan[143] - The company has implemented a performance-based compensation system linked to job value and contribution, enhancing its incentive mechanisms[158] - The company conducted 123 training sessions during the reporting period to enhance employee skills and strengthen corporate culture[160] - The company has a stock incentive plan in place, with 2,540,000 restricted shares granted to key management personnel, of which 1,016,000 shares have been unlocked[166]

贵州三力制药股份有限公司 独立董事年度述职报告 根据中国证监会《上海证券交易所股票上市规则》（2023年8月 修订）、《上市公司治理准则》、《上市公司独立董事管理办法》和 《贵州三力制药股份有限公司公司章程》（以下简称"《公司章程》"） 等有关规定，作为贵州三力制药股份有限公司（以下简称"公司"） 独立董事，本人勤勉尽责地履行独立董事职责，积极出席相关会议， 认真审议董事会各项议案，切实维护了公司整体利益和全体股东尤其 是中小股东的利益。 现就2023年度履职情况报告如下： 一、独立董事的基本情况 公司董事会由7名董事组成，其中独立董事3人，占董事会成员人 数的三分之一以上，符合相关法律法规及公司制度的规定。 本人王强：男，中国国籍，1970年1月生，无永久境外居留权， 工商管理硕士，会计师、审计师、中国注册会计师、中国注册资产评 估师。1993年7月至1996年9月任贵阳市审计局工交处审计员；1996 年10月至1999年10月任贵阳审计师事务所评估主任；1999年11月至今, 任贵阳安达会计师事务所副所长；2006年4月至今任贵州君安房地产 土地资产评估有限公司执行董事，贵州省注册会计师协会理事(曾任 中 ...

证券代码：603439 证券简称：贵州三力 公告编号：2024-018 贵州三力制药股份有限公司 关于首次公开发行股票募投项目结项并将节余 募集资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为进一步加强募集资金的管理和运用，提高募集资金使用效率，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司监管指引第2号—— 上市公司募集资金管理和使用的监管要求》和上海证券交易所发布的《上海证券 交易所上市公司自律监管指引第1号——规范运作》等有关法律法规和规范性文 件，结合公司实际情况，公司制订了《贵州三力制药股份有限公司募集资金管理 制度》。根据上述管理制度的规定，公司对募集资金实行专户存储。 公司已与保荐机构申港证券股份有限公司于2020年4月22日分别同贵阳银行 股份有限公司平坝支行、招商银行股份有限公司贵阳分行、中国工商银行股份有 限公司贵阳南明支行签订了《募集资金专户存储三方监管协议》。上述监管协议 明确了各方的权利和义务，协议主要条款与上海证券交易所《募集资金专户存 ...

贵州三力制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 活动召开方式：网络远程方式。投资者可在上述召开时间，通过"全景 路演"（网址：http://rs.p5w.net），在线参与本次活动，公司将及时回答投资 者的提问。 投资者可于本公告发出之日起至 2024 年 5 月 7 日，通过微信关注"贵 州资本市场"公众号，发送关键词"提问"，即可进入专区提问。公司将在本次 说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日在 上海证券交易所网站（http://www.sse.com.cn）上披露了《公司 2023 年年度 报告》及其摘要。为加强公司与投资者的交流互动，便于广大投资者更加全面 深入地了解公司 2023 年度的经营情况、公司治理及发展战略等。在贵州证监局 指导下，贵州证券业协会联合深圳市全景网络有限公司举办 2024 年贵州辖区上 市公司投资者集体接待日暨 2023 年度业绩说明会并征集相关问题。具体安排如 下： ...

章 程 贵州三力制药股份有限公司 | | | | 第一章总则 | | 3 | | --- | --- | --- | | 第二章经营宗旨和范围 | | 4 | | 第三章 | 股份 | 4 | | | 第一节股份发行 | 4 | | | 第二节股份增减和回购 | 5 | | | 第三节股份转让 | 7 | | 第四章 | 股东和股东大会 | 8 | | | 第一节股东 | 8 | | | 第二节股东大会的一般规定 | 10 | | | 第三节股东大会的召集 | 13 | | | 第四节股东大会的提案与通知 | 15 | | | 第五节股东大会的召开 | 18 | | | 第六节股东大会的表决和决议 | 21 | | 第五章 | 董事会 | 26 | | | 第一节董事 | 26 | | | 第二节董事会 | 29 | | 第六章 | 总经理及其他高级管理人员 | 34 | | 第七章 | 监事会 | 36 | | 第一节 | 监事 | 36 | | | 第二节监事会 | 37 | | 第八章 | 财务会计制度、利润分配和审计 | 39 | | | 第一节财务会计制度 | 39 | | | 第二节内部审计 | ...

附件 4 独立董事候选人声明与承诺 本人归东，已充分了解并同意由提名人贵州三力制药股份有限公 司董事会提名为贵州三力制药股份有限公司第四届董事会独立董事 候选人。本人公开声明，本人具备独立董事任职资格，保证不存在任 何影响本人担任贵州三力制药股份有限公司独立董事独立性的关系， 具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。并已根据 《上市公司高级管理人员培训工作指引》及相关规定取得独立董事资 格证书。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定 ...

附件 4 独立董事候选人声明与承诺 本人陈世贵，已充分了解并同意由提名人贵州三力制药股份有限 公司董事会提名为贵州三力制药股份有限公司第四届董事会独立董 事候选人。本人公开声明，本人具备独立董事任职资格，保证不存在 任何影响本人担任贵州三力制药股份有限公司独立董事独立性的关 系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。并已根据 《上市公司高级管理人员培训工作指引》及相关规定取得独立董事资 格证书。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政 ...

贵州三力制药股份有限公司 2023 年度会计师事务所履职情况评估报告 贵州三力制药股份有限公司（以下简称"公司"）聘请北京大华国际会计 师事务所（特殊普通合伙）（以下简称"北京大华国际"）作为公司 2023 年 度财务及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、 上市公司选聘会计师事务所管理办法》，公司对北京大华国际 2023年审计过程 中的履职情况进行评估。经评估，公司认为北京大华国际资质等方面合规有效， 履职保持独立性，勤勉尽责，公允表达意见。具体情况如下： 北京大华国际会计师事务所（特殊普通合伙）成立于 2008 年，主要从事证 券期货审计业务，央国企审计服务，此外还提供资产评估、税务、工程造价咨 询、管理咨询等综合专业服务。 截止2024年2月，北京大华国际合伙人37人，注册会计师150人，签署过证 券服务业务审计报告的注册会计师人数52人。 北京大华国际制定了明确的专业意见分歧解决机制。当项目组成员、项目 质 量复核人或专业技术部成员之间存在未解决的专业意见分歧时，需要咨询专 业技术部负责人。在专业意见分歧解决之前不得出具报告。2023年年度审计过 程中，北京大华国际就公司的所有 ...

贵州三力制药股份有限公司 募集资金存放与使用情况鉴证报告 北京大华核字[2024]00000137 号 北京大华国际会计师事务所 (特殊普通合伙 ) Beijing Dahua International Certified Public Accountants (Limited Liability Partnership) 贵州三力制药股份有限公司 募集资金存放与使用情况鉴证报告 （2023 年度） 目 录 页 次 一、 募集资金存放与使用情况鉴证报告 1-2 二、 贵州三力制药股份有限公司 2023 年度募集资 金存放与实际使用情况的专项报告 1-11 北京大华国际会计师事务所（特殊普通合伙） 北京市西城区阜成门外大街 31 号五层 519A [100071] 电话：86 (10) 6827 8880 传真：86 (10) 6823 8100 募集资金存放与使用情况鉴证报告 北京大华核字[2024] 00000137 号 贵州三力制药股份有限公司全体股东： 我们审核了后附的贵州三力制药股份有限公司（以下简称贵州三 力）《2023 年度募集资金存放与实际使用情况的专项报告》（以下简称 "募集资金专项报告"） ...